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A B S T R A C T   
Background: Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not 
enough scientific evidence to support this treatment. The objective of this study is to analyze whether the use of 
tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with COVID- 
19 and lung involvement. 
Methods: Observational study on a cohort of 418 patients, admitted to three county hospitals in Catalonia (Spain). 
Patients admitted consecutively were included and followed until discharge or up to 30 days of admission. A sub- 
cohort of patients treated with tocilizumab and a sub-cohort of control patients were identified, matched by a 
large number of risk factors and clinical variables. Sub-cohorts were also matched by the number of other 
treatments for COVID-19 that patients received. Increment in SAFI (inspired oxygen fraction / saturation) 48 h 
after the start of treatment, and time to discharge, were the primary outcomes. Mortality, which was a secondary 
outcome, was analyzed in the total cohort, by using logistic regression models, adjusted by confounders. 
Results: There were 96 patients treated with tocilizumab. Of them, 22 patients could be matched with an 
equivalent number of control patients. The increment in SAFI from baseline to 48 h of treatment, was not 
significantly different between groups (tocilizumab: − 0.04; control: 0.09; p = 0.636). Also, no difference in time 
to discharge was found between the two sub-cohorts (logrank test: p = 0.472). The logistic regression models, did 
not show an effect of tocilizumab on mortality (OR 0.99; p = 0.990). 
Conclusions: We did not find a clinical benefit associated with the use tocilizumab, in terms of respiratory 
function at 48 h of treatment, or time to discharge.   
1. Introduction 
A novel coronavirus (severe acute respiratory syndrome coronavirus 
2, SARS-CoV-2) causing an epidemic outbreak was reported in Wuhan 
(China) in December 2019 [1], being declared the outbreak as a 
pandemic on March 12, 2020 [2]. Although in most cases the symp-
tomatology is mild (approx. 80%) [3], the extent and total number of 
people affected have resulted in a considerable number of fatalities [4]. 
A significant proportion of mortality in these patients is linked to 
severe respiratory deterioration (acute respiratory distress syndrome) 
caused by an excessive immune system activation, similar to the cyto-
kine storm syndrome [5]. Interkeukin-6, which production may be 
increased by SARS-CoV-2, plays a potential role in this syndrome. As a 
result, it has been hypothesized that tocilizumab, a recombinant hu-
manized anti-interleukin-6 receptor monoclonal antibody, may have a 
beneficial effect on COVID-16 lung disease, especially in the most severe 
cases [5,6]. 
So far, the results of a single clinical trial investigating the efficacy of 
Tocilizumab in COVID-19 have been published [7]. In this trial, no 
benefit was observed in time to intubation or death, although the 
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authors acknowledge that the confidence intervals of the results are too 
wide to rule out some benefit or harm associated with the use of Toci-
lizumab in this disease. 
Regarding observational studies, only a few have considered a robust 
adjustment method for confounders [8–13], being the methods based on 
the Propensity Score, the most robust [14,15]. These methods, although 
more effective than multivariate analysis in reducing the probability of 
biases, decrease their matching performance when confounders change 
over time (time-dependent) [15], such as oxygen saturation or temper-
ature, which are relevant in the case of the evaluation of patients 
affected by Covid- 19. 
In this observational study on the efficacy of tocilizumab on COVID- 
19 hospitalized patients, we measured the improvement in lung function 
and time to discharge, as primary outcomes. We have used brute force 
algorithms to determine the moment of maximum similarity between 
groups, with respect to variables that change over time, which has 
allowed us to maximize the quality of matching between comparison 
groups. 
2. Design and methods 
2.1. Study design and settings 
Patients analyzed in this study are part of the COVID-19 cohort of the 
Consorci Sanitari de l’Alt Penedès i Garraf (CSAPG). CSAPG is a con-
sortium which brings together three regional hospitals in Catalonia, 
Spain, with a total reference population of 247,357 inhabitants from the 
regions of Alt Penedès and Garraf. The COVID-19 cohort of the CSAPG is 
made up of 418 consecutive patients admitted from March 12, 2020, to 
May 2, 2020. In this cohort, patients without respiratory symptoms and 
patients with negative nucleic acid test for SARS-CoV-2 in a sample 
obtained by nasal smear, were excluded. 
The investigators of the COVID-19 research group of CSAPG 
collected all data from the electronic medical records. The investigators 
collected sociodemographic data, comorbidities, previous chronic 
treatments and symptoms of presentation of COVID-19 disease. More-
over, every day since admission, the researchers recorded the vital signs 
of the patients, the inspired fraction of oxygen (FiO2), the peripheral 
pulse-oximetry values and all treatments given during the hospital stay. 
FiO2 values were recorded from the clinical history; FiO2 was always 
considered to be 28% for low flow nasal cannula and 100% for non- 
rebreathing masks. All blood tests and chest radiographs performed 
were also included in the database. Data were collected with the aid of a 
structured form created in the OpenClinica, version 3.1. (Copyright © 
OpenClinica LLC and collaborators, Waltham, MA, USA), following a 
common procedure on which all participants were previously trained. 
During the data collection process, quality controls were established on 
the data collected, correcting errors and retraining researchers, when 
necessary. 
2.2. Exposure and outcome variables 
In the study hospitals, Tocilizumab was used both as a single dose of 
600 mg intravenously, as well as in multidose regimens: initial dose of 
600 mg, second dose of 400–600 mg at 12 h, and a third optional dose of 
400 mg (depending on the evolution of the patient). For the purposes of 
this study, all patients who received at least one dose were considered 
exposed to tocilizumab. 
The primary outcomes were time to discharge and SAFI at 48 h after 
start of treatment. SAFI is a parameter related with respiratory function, 
which was calculated using the following formula: saturation (%) / 
FiO2(%). As secondary outcomes we studied the SAFI in the first 96 h 
after treatment, C-reactive protein (CRP) in the first 96 h after the start 
of treatment, and mortality. 
Fig. 1. Selection process for patient-matched controls.  
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2.3. Matched features 
In the statistical analysis, a subcohort of patients treated with toci-
lizumab was formed, and a control subcohort was matched with it (1:1 
match ratio). The patients were matched by the following basal char-
acteristics, which were identified as prognostic markers in previous 
bivariate analyses and multivariate models: sex, age, obesity, heart 
failure, chronic renal failure, and sleep apnea–hypopnea syndrome 
(SAHS). In addition the patients were matched by SAFI, vital signs 
(blood pressure, heart rate, and temperature), radiological involvement, 
CRP, and other COVID-19 treatments at the time of comparison. Vital 
signs were recorded by hospital nurses, as part of their routine daily 
practice, using the standard validated instruments of the hospital. 
2.4. Matching time frame 
Follow-up of each patient started the day the patient took the first 
dose of a study drug. Follow-up of each control started the day after 
admission on which SAFI, vital signs (blood pressure, heart rate, and 
temperature), radiological involvement, and CRP were similar to those 
of the patient with whom they were matched. For this purpose, the CRP 
on day 1 of follow-up of the patient or, failing that, the day before the 
start of treatment, was taken as reference. Likewise, the radiological 
involvement on the treatment started, or any previous time up to a 
maximum of two days before the start of treatment, was considered. 
Missing data on radiological involvement were imputed in the following 
way: It was assumed that the radiological involvement on the days be-
tween two equal radiographs was the same as on the days of said ra-
diographs (e.g., if a patient had an X-ray with three affected quadrants 
on day 1 and another with three affected quadrants on day 6, it was 
assumed that on all intervening days they had three affected quadrants). 
This interpolation was allowed up to a maximum interval of 6 days be-
tween radiographs. No missing data were imputed for other variables. 
Patients who received the study treatment and their controls were 
matched only if they had received the same other treatments for COVID- 
19, including hydroxychloroquine, lopinavir/ritonavir or azithromycin. 
A margin of 3 days of lag at the start of the other treatments was toler-
ated between the patients under study and the matched controls. In the 
study hospitals, corticosteroids were also used as disease’s treatment 
(mainly high doses of metilpredinosolone); in previous analysis we 
found no relationship between the use of these drugs and the study 
outcomes [16], thus we allowed the subcohorts to not be paired by 
corticosteroids (which facilitated greater availability of controls who 
were more similar other characteristics of interest). 
2.5. Matching technic 
For pairing, a first step was performed using brute-force computing 
algorithms, which identified all possible controls in the database for 
each of the patients who received the study treatment. In this first step, 
controls were chosen who had the same sex and state of obesity (“yes” vs 
“no”, according to the clinical history), the same radiological involve-
ment (number of affected quadrants on anteroposterior radiography: 
0–4) and an age difference not exceeding 15 ears. The control was 
allowed to have a SAFI from 1.1 points lower to 2 points higher than the 
treated patient and a CRP from 6 mg/dL lower to 4 mg/dL higher than 
the treated patient. The matching was then refined, choosing from 
among the previously identified potential controls the most similar in 
terms of SAFI, blood pressure, heart rate, and CRP by the propensity 
score. The same matching methodology has been used for the analysis of 
efficacy of other COVID-19 drugs in the CSAPG cohort [16–17]. The 
complete process of selecting patient pairs, including the procedures 
performed by the brute force algorithms, are summarized in Fig. 1. 
The success of the matching was verified by comparing means or 
percentages between groups. Although the cohorts were paired by all 
relevant variables the first day of comparison, we wanted to rule out a 
different trend in the evolution of patients such day (improvement in 
one group and worsening in another). To do so, we verified that in both 
groups, the difference in the SAFI was similar between day 1 of analysis 
and the day before entering the analysis. 
2.6. Statistical analysis 
In the matched subcohorts, the SAFI was studied at 48, 72, and 96 h 
using Student’s t-test for independent samples and the time to discharge 
was analyzed using the log-rank test. In the SAFI analyses, patients with 
palliative sedation were excluded because in these patients SAFI is not 
related to the severity of the disease. In the analysis of time to discharge, 
deceased patients were excluded. 
Due to the small sample size of the matched cohorts, association 
between tocilizumab use and mortality (proportion of events) was 
studied in the complete cohort, fitting logistic regression models, 
adjusted for other COVID medications (corticosteroids, hidroxiclor-
oquin, azithromycin, lopinavir/ritonavir, interferon) and the following 
confounders: sex, age, obesity, heart failure, chronic renal failure, SAHS, 
baseline saturation in the emergency room, CRP in the emergency room, 
and quadrants affected in the emergency radiography. 
For the statistical analysis, R software version 3.6.1 (R Project for 
Statistical Computing) and IBM SPSS statistics version 26 were used. 
2.7. Ethics 
Authors confirm that all methods were carried out in accordance 
with relevant guidelines and regulations, including the Declaration of 
Helsinki in its latest version and Regulation (EU) 2016/679 of the Eu-
ropean Parliament and of the Council of April 27, 2016 on Data 
Table 1 
Baseline characteristics of patients treated with tocilizumab and the matched 
controls.   
Tocilizumab (n22) Control (n22) p 
Age (years) 68.4 66.1 0.572 
Men (n) 18 18 1.000 
Obesity (n) 3 3 1.000 
CHF (n) 0 0 – 
CRF (n) 3 1 0.604 
SAHS (n) 1 1 1.000  
Saturation (%) 95.0 95.1 0.533 
Systolic BP (mmHg) 125.9 131.7 0.337 
Diastolic BP (mmHg) 72.1 74.3 0.483 
HR (bpm) 72.5 75.3 0.314 
Temperature (◦C) 36.4 36.7 0.191 
SAFIa 2.8 3.1 0.249 
SAFI trendb − 0.2 0.0 0.120 
Intubated patients 0 0 –  
Radiographic involvementc 2.3 2.3 1.000 
CRP (mg/dL) 10.8 12.7 0.345 
Urea (mg/dL) 35.4 (n12) 32.7 (n11) 0.600  
Hydroxychloroquine (n) 21 21 1.000 
Lop/Rit (n) 21 21 1.000 
Interferon (n) 2 0 0.488 
Tocilizumab (n) – – – 
Methylprednisolone (n) 10 7 0.537 
Dexamethasone (n) 6 1 0.095 
Azithromycin (n) 16 18 0.721 
CHF: congestive heart failure. CRF: chronic renal failure. SAHS: sleep 
apnea–hypopnea syndrome. BP: blood pressure. HR: heart rate. SAFI: saturation 
(%)/fraction of inspired O2 (%). CRP: C-reactive protein. 
a Maximum value 4.76, corresponding to 100% saturation with FiO2 of 21%. 
b Change in SAFI with respect to the day before the start of the follow-up 
period. 
c Number of affected quadrants in an anteroposterior chest radiograph. Range: 
0–4 (0: no involvement; 4: involvement of the upper and lower lobes of both 
lungs). 
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Protection (RGPD) and other concordant rules. The research ethics 
committee of the Hospital de Bellvitge (CSAPG’s tertiary referral hos-
pital) reviewed the study and accepted the waiver of the patient’s 
informed consent, as it was an observational and ambispective review of 
clinical data, and the patient’s personal data were anonymized for its 
publication (Ethics committee reference number: PR252/20). 
3. Results 
Of the 418 patients included in the COVID-19 cohort of the CSAPG, a 
total of 96 (23%) patients were treated with tocilizumab. Of them, 22 
patients could be paired with matched controls. The characteristics of 
the matched subcohorts are shown in Table 1. The characteristics of the 
matched subcohorts, after excluding deceased patients, and their con-
trols, are shown in Table 2. 
Compared with the rest of the patients who received tocilizumab, the 
patients selected for the matched cohort (matched control available), 
were older and had less severe disease (Table 3). 
Mean changes in saturation, FiO2, and SAFI, in the first 48, 72 and 
96 h after the start of the treatment, both in treated and untreated 
subcohorts, are shown in Table 4. 
Statistical power was estimated to be 79.7% for detecting an 
improvement of 3% of saturation in Tocilizumab group; 62.3% for 
detecting a 15% FiO2 reduction in Tocilizumab group; and 81.4% for 
detecting an increase of 0.7 points in SAFI. 
Comparing with control group, patients treated with tocilizumab 
presented a sustained CRP decrease after treatment. The absolute dif-
ference in CRP levels between groups were as follow: 199 mg/L at 48 h 
(p < 0.032), 118 mg/L at 72 h (p < 0.010) and 45.7 mg/L at 96 h 
(p < 0.006). 
The mean of follow up of the total patients included in the analysis 
was 8 days (interquartile range: 5 days). In average, patients in tocili-
zumab group were discharge in 9.3 days, this time was of 8.7 days for 
patients in control group. Time to discharge was not significantly 
different between treated and untreated patients (logrank: p = 0.462). 
Kaplan-Meier curves for the time to discharge in the treated and control 
subchorts, are shown in Fig. 2. Statistical power was calculated to be 
46.4% for a reduction of 3 days in hospital stay in tocilizumab group. 
Of the total cohort (N418), 79 patients died in the first 30 days after 
admission (18.9%). Adjusted logistic regression models, did not show an 
association between the use of tocilizumab and mortality: adjusted OR: 
0.99 (IC95: 0.30–3.27); p = 0.990. 
Table 2 
Baseline characteristics of patients treated with tocilizumab and the matched 
controls, after exclusion of deceased patients.   
Tocilizumab (n19) Control (n19) p 
Age (years) 64.8 66.1 0.766 
Men (n) 15 15 1.000 
Obesity (n) 3 3 1.000 
CHF (n) 0 1 0.312 
CRF (n) 3 4 0.680 
SAHS (n) 1 2 0.550  
Saturation (%) 95.2 95.6 0.533 
Systolic BP (mmHg) 127.5 130.5 0.568 
Diastolic BP (mmHg) 71.8 72.9 0.702 
HR (bpm) 72.9 76.7 0.198 
Temperature (◦C) 36.4 36.6 0.300 
SAFIa 2.8 3.0 0.429 
SAFI trendb − 0.2 0.0 0.092 
Intubated patients (n) 0 0 –  
Radiographic involvementc 2.4 2.4 0.504 
CRP (mg/dL) 11.5 13.3 0.512 
Urea (mg/dL) 37.6 (n14) 38.6 (n13) 0.900  
Hydroxychloroquine (n) 21 21 1.000 
Lop/Rit (n) 21 21 1.000 
Interferon (n) 2 0 0.488 
Tocilizumab (n) – – – 
Methylprednisolone (n) 10 7 0.537 
Dexamethasone (n) 6 1 0.095 
Azithromycin (n) 16 18 0.721 
CHF: congestive heart failure. CRF: chronic renal failure. SAHS: sleep 
apnea–hypopnea syndrome. BP: blood pressure. HR: heart rate. SAFI: saturation 
(%)/fraction of inspired O2 (%). CRP: C-reactive protein. 
a Maximum value 4.76, corresponding to 100% saturation with FiO2 of 21%. 
b Change in SAFI with respect to the day before the start of the follow-up 
period. 
c Number of affected quadrants in an anteroposterior chest radiograph. Range: 
0–4 (0: no involvement; 4: involvement of the upper and lower lobes of both 
lungs). 
Table 3 
Baseline characteristics of patients treated with tocilizumab, included in the 
matched cohort, compared with those treated with tocilizumab, for whom no 






Age (years) 58.4 66.1 0.020 
Men (%) 74.3 81.8 0.470 
Obesity (%) 31.1 13,6 0.106 
CHF (%) 1.4 0 1.000 
CRF (%) 9.5 13.6 0.691 
SAHS (%) 8.1 4.5 1.000  
Saturation (%) 94.3 96.0a 0.023 
Systolic BP (mmHg) 124.8 124.6a 0.951 
Diastolic BP (mmHg) 71.3 70.0a 0.628 
HR (bpm) 82.5 79.1a 0.262 
Temperature (◦C) 37.0 37.1a 0.898 
SAFIb 2.8 3.1a 0.249 
Intubated patients (%) 18.9 0 0.035  
Radiographic 
involvementc 
2.6 1.7a 0.001 
CRP (mg/dL) 17.6 8.9a 0.001 
Urea (mg/dL) 37.6 33.4a 0.347 
CHF: congestive heart failure. CRF: chronic renal failure. SAHS: sleep 
apnea–hypopnea syndrome. BP: blood pressure. HR: heart rate. SAFI: saturation 
(%)/fraction of inspired O2 (%). CRP: C-reactive protein. 
Bold indicates statistically significant results. 
a First day of admission values (may not coincide with those of the first day 
entering the matched cohort, sown in Table 1). 
b Maximum value 4.76, corresponding to 100% saturation with FiO2 of 21%. 
c Number of affected quadrants in an anteroposterior chest radiograph. Range: 
0–4 (0: no involvement; 4: involvement of the upper and lower lobes of both 
lungs). 
Table 4 
Increase in respiratory function parameters with respect to the first day of 
follow-up in patients treated with azithromycin, corticosteroids, and 
tocilizumab.   
Tocilizumab Control p 
Saturation increase    
48 h 0.67 (n22) − 0.63 (n22) 0.104 
72 h 0.44 (n20) − 0.64 (n21) 0.205 
96 h 0.53 (n18) − 1.54 (n19) 0.124  
FiO2 increase    
48 h 7.64 (n22) 1.71 (n22) 0.428 
72 h 0.81(n21) − 2.30 (n21) 0.652 
96 h − 1.85 (n20) − 2.35 (n19) 0.954  
SAFI increase    
48 h − 0.04 (n22) 0.09 (n22) 0.636 
72 h 0.37 (n20) 0.31 (n20) 0.824 
96 h 0.39 (n19) 0.26 (n19) 0.699 
FiO2: fraction of inspired oxygen. 
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4. Discussion 
We were unable to find a benefit associated to the use of tocilizumab 
in terms of respiratory function (SAFI) or time to discharge. However, 
we observed a significant decrease in CRP in patients treated with 
tocilizumab, which did not correlate with an improvement in the studied 
clinical parameters. This observation may indicate that the increased 
synthesis of CRP, which Tocilizumab reduces through IL-6 blocking, 
represents more of a host reaction against infection, rather than com-
ponents of a self-amplifying inflammatory loop that would benefit from 
CRP suppression [7]. 
None of the patients included in our paired cohort were intubated, so 
our results cannot be compared with those obtained in critically ill pa-
tients [9,10,12,13]. We found two observational studies, conducted on 
less severe patients, which used correct matching techniques to avoid 
biases [8,11]. None of them reported results on improvement in lung 
function, or time to discharge, therefore we cannot compare our primary 
endpoints with them. These studies found benefit in mortality / need for 
intubation with the use of tocilizumab in their respective cohorts of 778 
and 196 hospitalized patients, with clinical criteria of relevant systemic 
inflammation; their results do not coincide with the mortality results 
obtained by us, by using Cox regression analysis. Nor do the results of 
these observational studies coincide with the data released from the 
COVACTA randomized clinical trial, whose results has not been pub-
lished, but informally disseminated in ta press release [18]; the COVA-
CTA trial found no benefit in terms of mortality, in patients hospitalized 
for coronavirus pneumonia. This may be due to the fact that these 
observational studies, unlike ours, and unlike the COVACTA trial, used a 
specific inflammatory markers level as inclusion criteria, therefore, both 
our patients and those in the COVACTA trial may have a less significant 
inflammatory state. 
Our results support those of the only clinical trial published to date, 
which found no benefit in time to intubation (or time to death, if it 
happened before intubation), in patients hospitalized for COVID-19. In 
line with our results, the authors also found that CRP decreased at a 
faster rate in patients in the tocilizumab group compared to the control 
group. 
Given the observational nature of our study, the existence of residual 
confounders cannot be ruled out, as there is a greater probability that 
patients treated with tocilizumab, would have a higher-risk factors or 
disease severity. However, the exhaustive matching method used for 
studying the primary outcomes, and the verification of the compara-
bility of the groups lead us to assume that this confounding effect was 
unlikely and, if there, was small. The fact that we included the patients 
in the matched cohort on the first day of treatment, avoids immortality 
time bias. Furthermore, the verification of the trend in SAFI, with 
respect to the previous day, and the vital signs matching, reasonably 
rules out biases related to disease’s course time. 
The use of secondary data (obtained from the clinical history) might 
have led to information biases, as clinical data were not originally 
recorded for the purpose of this research. Nevertheless, given that the 
main variables were quantitative parameters, which were little influ-
enced by the observers or their expertise in measurement, and given that 
these parameters are routinely and properly collected in clinical prac-
tice, we consider unlikely the existence of a relevant bias of this type. 
Due to exhaustive matching, the final sample size of our comparison 
cohorts is small. This can lead to problems of generability, since our 
patients may not represent well the common of patients hospitalized for 
COVID-19. Specifically, our results cannot be applied to the most severe 
cases, which were not represented in our matched cohort. In addition, 
the small sample size leads to lack of statistical power, especially with 
regard to time to discharge calculations, which may prevent appreci-
ating existing differences between groups. The lack of statistical power 
also affected the study of mortality in the entire cohort, as can be seen in 
the width of the confidence intervals. However, given the similarity of 
the results means (whose differences are not clinically significant, and 
tend to favor control group), the authors believe that, if tocilizumab has 
a beneficial effect on SAFI in the first 96 h, on the time until discharge, or 
in mortality, this effect is not prominent (and, in any case, this effect 
should be less than its biological effect on PCR, which we have been able 
to detect in our sample). Thus, the sample size and observational nature 
of our study warrant waiting for the results of randomized clinical trials 
to confirm ours. 
In conclusion, in this observational study, we did not find evidence of 
a clinical benefit on post-treatment lung function (SAFI in the first 96 h) 
or on length of the hospital stay, associated to the use of tocilizumab in 
patients hospitalized with COVID-19. 
Fig. 2. Time to discharge in tocilizumab treated patients and paired controls. Kaplan-Meier comparison curves and log-rank test.  
A. Rodríguez-Molinero et al.                                                                                                                                                                                                                  
One Health 12 (2021) 100214
6
Author contributions 
ARM designed the study, contributed to data analysis and interpre-
tation, drafted the manuscript and approved the final version. 
CP designed algorithms for patient matching and aproved the final 
versión of the manuscirpt. 
CG contributed to the study design, data interpretation and drafting 
the manuscript. 
AM did the statistical analysis, reviewed and approved the final 
version of the manuscript. 
OM, GFL, MTR, MDD, SM, ER, IC and the COVID-19 research group 
of CSAPG, collected the data and reviewed and aproved the final versión 
of the manuscirpt. 
Declaration of Competing Interest 
The authors declare no competing interests. 
Acknowledgment 
This work was supported by the Consorci Sanitari de l’Alt Penedès i 
Garraf. 
We would like to thank Gloria Moes for her invaluable help in 
coordinating the fieldwork. Gloria Alba, Nuria Pola and Anna María 
Soler, for their initial help in collecting drug data, and to Montserrat 
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